Edition:
India

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,060.00GBp
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
1,060.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,181,391
52-wk High
2,346.00
52-wk Low
906.50

Chart for

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products... (more)

Overall

Beta: 1.34
Market Cap(Mil.): £2,897.33
Shares Outstanding(Mil.): 240.65
Dividend: 8.50
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Hikma Says Hikma Ventures Has Participated In Financing For Prognos​

* ‍VENTURE CAPITAL ARM, HIKMA VENTURES HAS PARTICIPATED IN A $20.5 MILLION SERIES C ROUND OF FINANCING FOR PROGNOS​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

30 Nov 2017

BRIEF-Hikma Pharmaceuticals ‍invests in biosensor tech firm Biolinq​

* HIKMA PHARMACEUTICALS PLC - ‍INVESTED IN BIOLINQ IN COLLABORATION WITH M VENTURES WHICH LED $10 MILLION SERIES A ROUND OF FINANCING​ Source text for Eikon: Further company coverage:

27 Nov 2017

BRIEF-Hikma Pharmaceuticals acquires six products from Boehringer Ingelheim GmbH

* ‍HIKMA ACQUIRES PRODUCTS IN EUROPE FROM BOEHRINGER INGELHEIM​

14 Nov 2017

Drugmaker Hikma cuts generics sales forecast a third time

Nov 9 Hikma Pharmaceuticals Plc on Thursday lowered 2017 revenue guidance for its generics business for a third time.

09 Nov 2017

BRIEF-Hikma Pharmaceuticals says ‍continue to expect FY revenue around $2.0 bln​

* ‍CONTINUE TO EXPECT FULL YEAR REVENUE TO BE AROUND $2.0 BILLION IN CONSTANT CURRENCY IN 2017​

09 Nov 2017

BRIEF-Hikma launches serious infections treatment in the United States

* ‍CAPSULES ARE INDICATED FOR TREATMENT OF SERIOUS INFECTIONS CAUSED BY SUSCEPTIBLE STRAINS OF CANDIDA AND/OR CRYPTOCOCCUS​ Source text for Eikon: Further company coverage:

03 Nov 2017

BRIEF-Hikma says US unit launched pantoprazole sodium for injection

* U.S. unit west-ward pharmaceuticals has launched pantoprazole sodium for injection, 40mg​ Source text for Eikon: Further company coverage:

30 Oct 2017

Drugmaker Hikma's U.S. unit raises medicine prices: Financial Times

NEW YORK Hikma Pharmaceuticals Plc's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday.

21 Aug 2017

Drugmaker Hikma's U.S. unit raises medicine prices -Financial Times

NEW YORK, Aug 20 Hikma Pharmaceuticals Plc's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday.

21 Aug 2017

UPDATE 2-Drugmaker Hikma trims sales forecasts, shares fall

Aug 17 Hikma Pharmaceuticals Plc on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low.

17 Aug 2017

Earnings vs. Estimates